N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

A series of N-(4-(6,7-disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides targeting c-Met and VEGFR2 tyrosine kinases was designed and synthesized. The compounds were potent against these two enzymes with IC(50) values in the low nanomolar range in vitro, possessed favorable pharmacokinetic profiles and showed high efficacy in vivo in several human tumor xenograft models in mice.

[1]  P. Comoglio,et al.  Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.

[2]  David S. Nirschl,et al.  Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. , 2008, Bioorganic & medicinal chemistry letters.

[3]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[4]  J. Fargnoli,et al.  Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. , 2009, Journal of medicinal chemistry.

[5]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[6]  Michael Reggelin,et al.  Syntheses of novel 2,3-diaryl-substituted 5-cyano-4-azaindoles exhibiting c-Met inhibition activity. , 2009, Bioorganic & medicinal chemistry letters.

[7]  J. P. Bowen,et al.  Molecular design and clinical development of VEGFR kinase inhibitors. , 2007, Current topics in medicinal chemistry.

[8]  K. Rex,et al.  c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations* , 2008, Journal of Biological Chemistry.

[9]  B. Ruggeri,et al.  Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. , 2004, Current medicinal chemistry.

[10]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Normanno,et al.  Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. , 2006, The oncologist.

[12]  Konstantin V Balakin,et al.  VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.

[13]  S. Schenone,et al.  Antiangiogenic agents: an update on small molecule VEGFR inhibitors. , 2007, Current medicinal chemistry.

[14]  D. Bottaro,et al.  Targeting the c-Met Signaling Pathway in Cancer , 2006, Clinical Cancer Research.

[15]  C. Meier,et al.  Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. , 2009, Bioorganic & medicinal chemistry letters.

[16]  R. Salgia,et al.  MET as a target for treatment of chest tumors. , 2009, Lung cancer.

[17]  G. V. Vande Woude,et al.  Showering c-MET-dependent cancers with drugs. , 2008, Current opinion in genetics & development.

[18]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[19]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[20]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[22]  C. Massard,et al.  Inhibiteurs de tyrosine kinase ciblant le VEGFR , 2006, Oncologie.

[23]  M. Robert,et al.  Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. , 2008, Bioorganic & Medicinal Chemistry Letters.

[24]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[25]  J. Fargnoli,et al.  Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. , 2008, Journal of medicinal chemistry.

[26]  Luca Toschi,et al.  Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer , 2008, Clinical Cancer Research.

[27]  J. Dumas,et al.  VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures , 2005, Expert opinion on therapeutic patents.

[28]  M. Robert,et al.  N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[29]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[30]  R. Salgia,et al.  Review of clinic trials: agents targeting c-Met. , 2007, Reviews on recent clinical trials.

[31]  J. Cui.  Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications , 2007 .

[32]  S. Bellon,et al.  From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. , 2009, Anti-cancer agents in medicinal chemistry.

[33]  Structure activity relationships of quinoline-containing c-Met inhibitors. , 2008, European journal of medicinal chemistry.

[34]  J. Fargnoli,et al.  Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[35]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[36]  Yuan Cheng,et al.  Design, synthesis, and biological evaluation of potent c-Met inhibitors. , 2008, Journal of medicinal chemistry.

[37]  K. Rex,et al.  Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). , 2008, Journal of Medicinal Chemistry.

[38]  G. Fisher,et al.  Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer , 2007, Expert opinion on investigational drugs.

[39]  C. Meier,et al.  Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase. , 2009, Bioorganic & medicinal chemistry letters.

[40]  Zhen-ping Zhu,et al.  Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. , 2005, Frontiers in bioscience : a journal and virtual library.

[41]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[42]  J. Christensen,et al.  A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.

[43]  K. Rex,et al.  Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. , 2008, Journal of medicinal chemistry.

[44]  Alexander D. MacKerell,et al.  Computational identification of inhibitors of protein-protein interactions. , 2007, Current topics in medicinal chemistry.

[45]  B. Vanhaesebroeck,et al.  Killing two kinase families with one stone. , 2008, Nature chemical biology.

[46]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[47]  J. Cui.  Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases , 2006, Expert opinion on therapeutic patents.